Catia Simoes

Catia Simoes

Auto-generated profile, based on publicly available information

Catia Simoes

Cancer Center Clinica Universidad de Navarra, Centro de Investigación Médica Aplicada (CIMA), IDISNA, CIBER-ONC number CB16/12/00369 and CB16/12/00489, Pamplona, Spain

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 November 2022 in Frontiers in Oncology
Verified
Journal Article
Open access
SVSara Villar
Sara Villar
BGBeñat Ariceta Ganuza
Beñat Ariceta Ganuza
XAXabier Agirre
Xabier Agirre
AUAura Daniela Urribarri
Aura Daniela Urribarri
RAROSA AYALA
ROSA AYALA
PMPau Montesinos
Pau Montesinos
Acute myeloid leukemia (AML) in the elderly remains a clinical challenge, with a five-year overall survival rate below 10%. The current ELN 2017 genetic risk classification considers cytogenetic and mutational characteristics to stratify fit AML patients into different prognostic groups. However, this classification is not validated for elderly patients treated with a non-intensive approach, and its performance may be suboptimal in this context. Indeed, the transcriptomic landscape of AML in the elderly has been less explored and it might help stratify this group of patients. In the current study, we analyzed the transcriptome of 224 AML patients > 65 years-old at diagnosis treated in the Spanish PETHEMA-FLUGAZA clinical trial in order to identify new prognostic biomarkers in this population. We identified a specific transcriptomic signature for high-risk patients with mutated TP53 or complex karyotype, revealing that low expression of B7H3 gene with high expression of BANP gene identifies a subset of high-risk AML patients surviving more than 12 months. This result was further validated in the BEAT AML cohort. This unique signature highlights the potential of transcriptomics to identify prognostic biomarkers in in elderly AML.

10 January 2023 in Blood Advances
Verified
Journal Article
Open access
PDF file
CSCatia Simoes
Catia Simoes
MCM. Carmen Chillon
M. Carmen Chillon
DMDavid Martínez-Cuadrón
David Martínez-Cuadrón
MCMaria José Calasanz
Maria José Calasanz
MVMaría-Belén Vridiales
María-Belén Vridiales
Bruno David Lourenco PaivaBruno David Lourenco Paiva
Bruno David Lourenco Paiva
Clonal evolution in acute myeloid leukemia (AML) originates long before diagnosis and is a dynamic process that may affect survival. However, it remains uninvestigated during routine diagnostic workups. We hypothesized that the mutational status of bone marrow dysplastic cells and leukemic blasts, analyzed at the onset of AML using integrated multidimensional flow cytometry (MFC) immunophenotyping and fluorescence-activated cell sorting (FACS) with next-generation sequencing (NGS), could reconstruct leukemogenesis. Dysplastic cells were detected by MFC in 285 of 348 (82%) newly diagnosed patients with AML. Presence of dysplasia according to MFC and World Health Organization criteria had no prognostic value in older adults. NGS of dysplastic cells and blasts isolated at diagnosis identified 3 evolutionary patterns: stable (n = 12 of 21), branching (n = 4 of 21), and clonal evolution (n = 5 of 21). In patients achieving complete response (CR), integrated MFC and FACS with NGS showed persistent measurable residual disease (MRD) in phenotypically normal cell types, as well as the acquisition of genetic traits associated with treatment resistance. Furthermore, whole-exome sequencing of dysplastic and leukemic cells at diagnosis and of MRD uncovered different clonal involvement in dysplastic myelo-erythropoiesis, leukemic transformation, and chemoresistance. Altogether, we showed that it is possible to reconstruct leukemogenesis in ∼80% of patients with newly diagnosed AML, using techniques other than single-cell multiomics.

19 June 2024 in Blood Neoplasia
Verified
Journal Article
Open access
CSCatia Simoes
Catia Simoes
CGCarmen Gonzalez
Carmen Gonzalez
FVFrancois Vergez
Francois Vergez
ASAudrey Sarry
Audrey Sarry
SBSarah Bertoli
Sarah Bertoli
FRF. Rojas
F. Rojas

2 November 2023 in Blood
Verified
Journal Article
Open access
CGCarmen Gonzalez
Carmen Gonzalez
CSCatia Simoes
Catia Simoes
BGBeñat Ariceta Ganuza
Beñat Ariceta Ganuza
DMDavid Martínez-Cuadrón
David Martínez-Cuadrón
JBJuan Miguel Bergua Burgues
Juan Miguel Bergua Burgues
Bruno David Lourenco PaivaBruno David Lourenco Paiva
Bruno David Lourenco Paiva
Disclosures. Martinez-Cuadron:Pfizer: Other: Travel, Accommodations; Astellas: Consultancy, Speakers Bureau; Otsuka: Consultancy, Other: Travel, Accommodations.

14 April 2023 in British Journal of Haematology
Verified
Journal Article
Closed access
CSCatia Simoes
Catia Simoes
SVSara Villar
Sara Villar
BABeñat Ariceta
Beñat Ariceta
JGJuan-José Garcés
Juan-José Garcés
LBLeire Burgos
Leire Burgos
TGthe PETHEMA cooperative study group
the PETHEMA cooperative study group